Navigation Links
Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
Date:5/1/2009

ALISO VIEJO, Calif., May 1 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced members of its senior management team will make a presentation at the Bank of America and Merrill Lynch 2009 Health Care Conference on Thursday, May 14, 2009 at 10:00 a.m. EDT. The conference will be held at The Palace Hotel in New York, NY.

A live webcast and audio archive of the presentation will be available on the company's Web site at www.valeant.com. Click on Investor Relations, and then the link to Events and Presentations. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. The webcast also can be accessed through the following URL: http://www.veracast.com/webcasts/bas/healthcare09/id84304207.cfm

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

    Contact:
    Laurie Little
    Valeant Pharmaceuticals
    949-461-6002

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
2. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
3. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
4. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
5. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
6. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
7. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
8. Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... education and high-level training standards for healthcare treatment providers who treat the full ... its Presidents Council. , The Presidents Council consists of the leading eating ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... University is taught by healthcare management and evaluation leaders with decades of experience ... to pay-for-value in the United States healthcare system, there is a renewed demand ...
(Date:1/23/2017)... ... January 23, 2017 , ... The ... America for the scientific development, healthcare training and clinical application of medical infrared ... 2017 AAT Member Certification Qualification Courses for Technicians, respectively. , For the first ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... Crystallization in Process Chemistry by Applying Simple PAT Tools . , ... to isolate and purify the desired product. Chemists now spend more time ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... earned organic certification under the USDA National Organic Program (NOP) for its Portland ... we have established organic production and handling systems to complement our current rigorous ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , Jan. 23, 2017  Therabron Therapeutics, ... a new standard in respiratory care, today announced ... Orphan Medicinal Products has granted Orphan Drug Designation ... of Bronchiolitis Obliterans Syndrome (BOS).  "We ... from the EMA to treat patients diagnosed with ...
(Date:1/23/2017)... , Jan. 23, 2017 Research and ... Market - Forecast to 2021" report to their offering. ... The interventional radiology ... from USD 6.35 Billion in 2016, at a CAGR of 4.8%. ... The major factors driving the growth of this market ...
(Date:1/23/2017)... 2017 Direct-to-consumer digital ... sold and 65% increase in consumable sales, quarter-over-quarter ... (NASDAQ: DRIO ), a leader in digital ... the Dario™ Blood Glucose Monitoring System, an all-in-one diabetes ... app-based and minimally invasive smart diabetes management solution. ...
Breaking Medicine Technology: